Mr. Morra joined the Akonni board in 2015. He has over 35 years of experience in general management, strategic planning, and business development in the aerospace and defense industry. Mr. Morra retired from Northrop Grumman Corporation in October 2016 where he was responsible for strategy, mergers and acquisitions, and investment planning in Northrop Grumman Corporation’s most profitable business unit – the Mission Systems Sector, which has annual revenues of $12B. He was a member of the Northrop Grumman corporate Strategic Development Council, providing direct advice to Northrop Grumman’s Chief Executive Officer and his immediate staff. From 2006 through 2010 Mr. Morra was the Electronics Systems Sector’s Vice President for Business Development and Customer Relations. He led the Sector’s international and domestic marketing and all business development activities. During his first assignment with Northrop Grumman he served from 2004 to 2006 as Vice President of Business Development in Northrop Grumman’s Mission Systems Sector. Prior to joining Northrop Grumman in December 2004, Mr. Morra was General Manager of the Transformation & Simulation business unit at General Dynamics. This business grew at an annual rate of 35% under Mr. Morra’s leadership. Prior to the acquisition of Veridian Corporation by General Dynamics in 2003, he served for five years as President of Veridian’s Advanced Systems & Technology Sector – a high technology business with commercial and government clients. Mr. Morra served 11 years as an executive at the privately held firm Pacific-Sierra Research Corporation. After a series of increasingly responsible management positions, Mr. Morra was appointed Senior Vice President and Chief Operating Officer of the company. Pacific-Sierra Research was acquired in 1998 by Veridian. Mr. Morra’s government service includes a combined 15 years active and reserve duty in the U.S. Air Force as an intelligence officer. Mr. Morra received a Bachelor of Arts degree from the College of William & Mary, a Master’s degree in public administration from the University of Oklahoma, and a Master’s degree in government and national security studies from Georgetown University. He is a graduate of Harvard Business School’s Advanced Management Program and the Aspen Institute’s Executive Strategy Course. He attended the U.S. Air Force’s Air Command and Staff College and several additional military and government schools. He also has served as a faculty member at the Joint Military Intelligence College and at the United States Air Force’s Air Command and Staff College. He is President of the College of William and Mary’s Graduate School of Arts and Sciences Advisory Board. He was a long-time member of the advisory board at the University of Virginia’s School of Engineering and Applied Sciences. Mr. Morra is a former director of the CEA Corporation, with headquarters in Canberra, Australia. He is a current member of the Board of Regents and a Senior Fellow of the Potomac Institute for Policy Studies.
Dr. Daitch is the Founder of Akonni and has served as the CEO and Board member since its inception in 2003. He has 26 years of product development experience in integrated biosensors encompassing a broad range of disciplines including chemistry, biology, biomaterials, engineering, and chemical/biological defense. He manages and leads multidisciplinary teams of scientists and engineers focused on the development of next-generation in-vitro diagnostic devices. Dr. Daitch has experience in developing a wide variety of sensor system products for remote autonomous or point-of-use detection of complex samples employing miniaturized analyte purification, and specialty biomaterials interfaced with microfabricated detection components coupled to a variety signal transduction modalities. He brings strong product development and R&D experience from the NIH/FDA, USDA, Sandia National Labs and the Intelligence Community. In addition, he has commercial senior management experience (P&L responsibility) from PSR/Veridian, CUBRC, HandyLab, and Akonni. Dr. Daitch was recruited by HandyLab Inc., a microfluidics diagnostic company, to serve on the executive management team as Vice President of R&D. Prior, Dr. Daitch launched a biodefense product development facility and business unit for PSR/Veridian Corp., a premier DOD/IC contractor, and led the growth of the operation to 24 employees and >$5M in annual revenue. As the CEO of Akonni he is responsible for 1) setting and executing strategic direction, 2) product management, 3) leading equity financing rounds (>$30M to date), managing capital, financial audits, 4) corporate governance, shareholder relations, 5) leading business development, strategic partnerships, 6) recruiting, mentoring, listening and learning from our exceptional staff, and 7) setting the company’s culture. He has 5 U.S. patents, 24 publications and served as principle investigator on over $20 million in government grants and contracts.
Michael Farmer served as the Chairman of the Board of Akonni Biosystems from 2004 to 2012. Michael recently retired from Prosetta Biosciences having served as President and Co-CEO for 13 years. Prior to joining Prosetta as a startup, he served as President and CEO of HandyLab, a biotech located in Ann Arbor MI. Previously, Mr. Farmer was COO of Veridian, a billion-dollar defense contractor that operated the world’s most advanced cyber security tools and services for protecting the most sensitive computer networks for government agencies. He was the managing partner in WindRiver Group, a professional consulting firm that provided strategic advice to senior management in both major companies and smaller growth and start-up companies. As President and CEO of Infotronics and COO of its parent, American Medical Communications, Houston-based medical communications and information companies, Mr. Farmer brought these $10 million companies to profitability within one year after a six-year history of losses. Mr. Farmer also co-founded Age Wave, a firm that consults with Fortune 500 business leaders and government agencies in the challenges and opportunities of the aging of America. He was COO of the Hospital Satellite Network (HSN) during its startup years. As Executive Vice President of Harbridge House, the Boston-based management consulting firm formed by professors from the Harvard Business School, Mr. Farmer headed up the firm’s national healthcare and defense practices over a ten-year period. Following initial college graduation, Michael worked as an engineer holding various classified positions in the Department of Defense and intelligence agencies. During those ten years, he lived in Hawaii, the South Pacific and Southeast Asia, principally worked with high technology Navy engineering systems and communications and computer systems. He also attended extensive nuclear power training, U.S. Navy diving training, and earned a pilot license while on assignment within the Naval Sea Systems Command. He holds degrees in engineering and business. Michael has been a moderator at the Aspen Institute wherein he graduated from the Institute’s flagship Executive Leadership Development Program and has served as a guest lecturer in Harvard’s Advanced Management Program, at the Haas School of Business Administration at University of California Berkeley and at the University of Michigan’s MBA graduate program.
Mr. Higgins joined the Akonni Biosystems Board in 2011 and has served as Akonni’s Chairman of the Board since 2013. He is a member of the Board of Directors for Prosetta Biosciences, Inc., a biotech drug development company. Mr. Higgins also served as Prosetta’s founding President and CEO from 2003-2008. Before that time, Mr. Higgins was President and Chief Operating Officer of Business for Social Responsibility (BSR). BSR is the leading global resource for businesses seeking to improve their performance in areas of corporate social responsibility. Mr. Higgins served in the administration of President Carter, beginning as a senior executive at the Department of Health Education and Welfare, where he was Director of Region VII, and at HHS, as Associate Commissioner of the Social Security Administration. His service culminated as a presidential appointee on the White House Senior Staff, where he served as Deputy Secretary to the Cabinet. Mr. Higgins has served as a senior vice president of Edison International and its subsidiary, Southern California Edison, and as a Senior Vice President of Blue Cross and Blue Shield of MD. Earlier in his career, he was head of the health department in Portland, Oregon; founding publisher of the Portland Business Journal; co-founder and Editor in Chief of HealthWeek Publications; and a three term state representative in Iowa. Mr. Higgins currently serves on the boards of directors of Zen Hospice Project, C-TAC, SCAN Health Plan and The SCAN Foundation. He is a member of the Board of Trustees of St. Ambrose University, where he graduated cum laude in 1967. He is also a co-founder and chairman of the board of Amber Kinetics, an energy storage company in Union City, Ca.
Mr. Keys serves as an Independent Financial and Operations Consultant. His current engagements include financial and operational oversight of a substantial real estate holdings and development company, commercial ranch and farming operations and a large investment portfolio of a number of startup and early stage companies. David began his career with Deloitte (one of the now Big 4 accounting firms) serving in the audit group in the Las Vegas and New York City executive offices. David was the Executive Vice President and CFO of American Pacific Corporation, a publicly traded chemical company for a number of years. Mr. Keys currently serves as Chairman of the Board and Audit Committee of RSI International Inc., a public company traded under the symbol RSY on the TSVX Exchange. He previously served on the Boards of Directors of two other publicly traded companies, AmFed Financial (NASDAQ) and American Pacific Corporation (NASDAQ). David was a member of the executive committee of the American Pacific Board of Directors. He was a member of the Boards of Directors of Norwest Bank of Nevada and Wells Fargo Bank of Nevada. Mr. Keys previously served on the Advisory Board of Directors of FM Global (formerly Factory Mutual Insurance), a leading provider of property and casualty insurance. He currently serves on the Board of Directors of a number of privately held companies including Prosetta Biosciences Inc. (Audit Committee Chair), Hauls Inc., Skywire Media Inc. (Chairman of the Board and Interim CEO), Walker Digital Table Systems LLC and Coast Flight Training and Management Inc. David is a Certified Public Accountant (CPA), Certified Valuation Analyst (CVA), Certified Management Accountant (CMA), Certified in Financial Forensics (CFF), Chartered Global Management Accountant (CGMA), Certified Information Technology Professional (CITP) and Certified in Financial Management (CFM). Mr. Keys is a member of the National Roster of Neutrals (sometimes referred to as the Commercial Panel) of the American Arbitration Association and has served as the sole arbitrator and as a member of a panel of three arbitrators on several cases in the Western United States, principally involving contract and valuation disputes. He received a Bachelor of Science degree in Accounting from Oklahoma State University in 1978. Mr. Keys joined the Akonni Biosystems Board in 2014.
Mr. McMahon serves as the President & CEO of CUBRC Inc., an independent, scientific not-for-profit (501c3) corporation, and of Avarint, LLC, its wholly-owned subsidiary. He has 32 years of experience in cultivating, securing, performing and managing highly diverse research, development, testing and integration programs and businesses focused on developing and advancing leading-edge technologies and systems in the areas of high speed aeronautics, public transportation and safety, data science and information fusion, modeling and simulation and (his personal area of expertise) chemical, biological and biomedical sciences. As President & CEO, he is ultimately responsible for all of CUBRC’s and Avarint’s strategic planning, program development activities, technical and business operations, infrastructure, compliance and financial performance. Outside of CUBRC, Mr. McMahon served from 2006 to 2009 as a Director on the Board of Prosetta Biosystems, Inc., a viral therapeutics start-up; has served as a Director of the Hauptman-Woodward Medical Research Institute since 2011; serves as a Director of HarkerBio, LLC since earlier this year; and has served as a Director of Trove Predictive Data Science since 2014. Mr. McMahon has a B.S. degree in Chemistry from St. Bonaventure University and an M.B.A. in Finance from Canisius College. Mr. McMahon joined the Akonni Biosystems Board in 2005.
Mr. Parrish, formerly Co-founder and Executive Vice President of Phone.com (PHCM) in Redwood City, California, is now a private investor and advisor to several technology companies. Before Openwave, Mr. Parrish was Vice President of marketing and General Manager of Mobile Data for GTE Mobile Communications (now Verizon (VZ). Prior to that, he was Senior Vice President of operations at Contel Cellular, Inc. and Co-founder and CEO of AmeriCom Corp in Atlanta. Mr. Parrish also served as Chief of Staff in the US Department of Interior during the Carter Administration, Carter/Mondale Texas Campaign Manager during the 1976 general election and National Field Director during the 1979-1980 Carter/Mondale primary campaign. Mr. Parrish served as a Division Director in the Georgia Department of Natural Resources under Governors Jimmy Carter and George Busbee. Mr. Parrish is a member of the Boards of CoEfficient LLC in Oakland CA; Akonni Biosystems in Frederick, MD; and Prosetta Biosciences (observer). He is a former Board Member of Novarra, Inc. (now Nokia), in Itasca, IL; the Corporation for Enterprise Development, in Washington, DC; and the Family Independence Initiative in Oakland, CA (Founding Chair). Mr. Parrish is married with two grown children and splits his time between Sarasota, FL and Martha’s Vineyard, MA. Mr. Parrish joined the Akonni Biosystems Board in 2009.
Mary A. Pittman, DrPH, is Chief Executive Officer and President of the Public Health Institute (PHI) in Oakland, California, one of the 15 largest non-profits in the Bay Area. Throughout her career, she has spearheaded efforts to align health care and public health sectors into order to improve population health and build equity. She is nationally recognized for her leadership in improving community health, addressing health inequities among vulnerable people and promoting prevention and quality of care. During her tenure, PHI has expanded their global portfolio, emphasizing women and girl’s empowerment and NCDs. PHI has expanded their research and data strategies to improve population health and equity, built strong web-based education through Dialogue4Health, built robust public-private partnerships, and has been recognized as one of the 50 best nonprofit workplaces in the nation. Pittman emphasizes the use of multi-sectoral models for community engagement and community building, incorporating innovative data and communication tools. She serves on numerous national boards and commissions. Pittman previously headed the Health Research and Educational Trust, an affiliate of the American Hospital Association, and the California Association of Public Hospitals.
Jialu Wu, MD, is the partner and member of investment committee in CDBI, a China based healthcare Venture Capital fund with >$600 million under management. Dr. Wu has 15+ years experience in medical practice, healthcare research and investment. He started his investment career from Qiming Venture Partners in 2011. Before that, he worked as the Medical Affairs Physician for GSK and Merck during 2009-2010. Jialu obtained his Medical Doctor degree from Peking Union Medical College in 2003, and worked as a physician in Cardiology in Shanghai First People’s Hospital for 6 years ever since.
TruDiagnosis Systems, TruDx Readers, TruArray Tests, TruTip Kits, Primers, Lysis and Binding Buffers, Wash Buffers and Elution Buffers: For Research Use Only. Not for use in diagnostic procedures. No claim or representation is intended to provide information for the diagnosis, prevention or treatment of a disease.